PDT and Iridex formalize photodynamic therapy device co-development pact.
This article was originally published in The Gray Sheet
Executive Summary
PDT, IRIDEX FORMALIZE PHOTODYNAMIC THERAPY DEVICE CO-DEVELOPMENT PACT with a May 28 agreement, PDT states. The two firms began working together about 12 months ago under an informal agreement to develop a light source to activate PDT's photodynamic therapy drug candidate, SnET2 (tin ethyl etiopurpurin), for the treatment of choroidal neovascularization associated with advanced age-related macular degeneration (AMD). Phase I/II clinical studies of the combination product commenced May 8.
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.